Responsibilities

• Develop and maintain strategic relationships with key academic and community thought leaders within assigned geography
• Identify emerging thought leaders and evolving treatment landscape trends
• Support ongoing engagement with KOLs, investigators, and key external stakeholders relevant to darovasertib and future pipeline assets
• Gather, synthesize, and communicate actionable marketplace insights to cross-functional stakeholders
• Identify opportunities to strengthen IDEAYA's presence within the melanoma and ocular oncology ecosystem
• Partner with Commercial Strategy & Marketing to support launch planning and execution activities
• Develop and execute regional strategic plans aligned to launch objectives and the overall Uveal Melanoma commercialization strategy
• Provide regional insights to inform segmentation, targeting, messaging, and account planning
• Collaborate with cross-functional teams to support launch readiness initiatives
• Support speaker identification, onboarding, and training initiatives

Requirements

• Bachelor’s degree required; advanced degree preferred
• 8+ years of biotechnology/pharmaceutical industry experience with oncology focus preferred
• Experience in Brand marketing
• Experience in Thought leader engagement
• Experience in Field strategy / Sales
• Experience in Commercial launch planning
• Experience in Market development
• Demonstrated ability to build and maintain relationships with oncology thought leaders
• Demonstrated excellence in oncology commercialization, launch execution, and business planning
• Excellent communication, collaboration, and strategic thinking skills

Preferred

• Advanced degree preferred.
• KOL engagement experience in oncology and especially rare oncology is preferred.
• New oncology product launch experience is preferred.

Benefits

• Our comprehensive benefits package includes, but is not limited to, medical/dental/vision coverage (100% company paid for employees and 90% company paid for dependents), 401k, ESPP, and wellness programs.